The article emphasizes key considerations like ensuring terminological clarity to prevent misunderstandings, the importance of transparency in communication, and how these factors collectively influence stakeholder understanding and acceptance.
This article describes how behavioral science can be applied in cardiometabolic clinical research to augment drug interventions. This combined approach addresses the Health Inequity gap while also increasing patient engagement.
The recent FDA publication “Submitting Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials” represents a significant leap forward in cancer research and drug development. This detailed guidance for integrating PROs into the drug approval process sets a new standard for the evaluation of cancer treatments.
Technological advancements have broadened the reach of clinical studies to larger and more diverse populations. However, technology alone isn’t sufficient to guarantee successful trial outcomes. The human element, including how technology is utilized by sites, sponsors, and patients in accordance with regulatory guidelines, remains pivotal in ensuring compliance, minimizing risks, and upholding patient safety.
There is an ongoing debate about the most efficient and ethical approach to reviewing electronic Clinical Outcome Assessments (eCOA).
Decentralized Clinical Trials (DCTs) have changed the way clinical research is conducted, transforming traditional approaches and introducing innovative methodologies.
Effective management of blood glucose levels is crucial for individuals with diabetes to prevent complications and improve their quality of life. However, traditional methods of glucose monitoring are often inconvenient, inaccurate, and incomplete.
When patients present for treatment at a clinic, physicians are trained to combine the results of objective assessments with their general observations to form a more complete picture of the patient’s health status.
The Enhancing Oncology Model (EOM) is a voluntary, patient-centered healthcare payment model developed by the Centers for Medicare & Medicaid Services (CMS) to improve cancer care delivery and outcomes while reducing costs.
Sponsors considering using data from sensors and wearables in their clinical trials worry about three scenarios: collecting too little data, collecting too much data, and collecting bad data. Each outcome could likely impact their study or a portion of it with a significant waste of time, money, and patient goodwill.
Clinical Ink’s Chief Innovation Officer, Joan Severson, joined a group of panelists on The Real Chemistry podcast during this year’s SXSW to provide insight into how the use of innovative data sources for clinical trial recruitment has become increasingly important in recent years.
Analyzing data collected through our collaborative Watch-PD study, we demonstrated digital biomarkers could detect both the presence of Parkinson’s disease (PD) as well as response to treatment.
Sales and Solutions
Direct 1.336.464.0697
Support
Toll-Free 1.800.301.5033
Direct 1.336.464.0697
Insert HTML text here.
Request more information, submit questions, set up a demonstration, and more.
